Administered by licensed Nurses and offered at our Draper, Layton, and Heber City, UT clinics
They can do so without needing to go through any FDA approval process
Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously and has shown promising results in early-phase clinical trials
Lomairas new dosage form allows for more flexibility and tailoring of treatment approaches, and it is more affordable than most medications approved for weight management
The TDP-43 Q331K transgenic mice weigh more than their wild type litter mates and gradually gain weight 25
As an experienced MSK provider, Omada is uniquely positioned to fill the biggest gap in GLP-1 care: maintaining weight through targeted exercise and nutrition, said Omada Health Chief Medical Officer Carolyn Bradner Jasik, MD